| Name | Title | Contact Details |
|---|
Iatroware is a Midland, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Zwanger Pesiri Radiology Group is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Lindenhurst, NY. To find more information about Zwanger Pesiri Radiology Group, please visit www.zwangerpesiri.com
Unchained Labs is committed to building the first cool biologics tools company. One with products that`ll make a real difference in the research scientists do every day. One that UNleashes tools that help them characterize their biologics better. Founded in January 2015, we have raised $31M of venture capital and have purchased two product lines. First, we let loose the UNit, the world`s first and only multiplex protein stability platform. Next we landed another big win with ICD, the world`s first quantitative stability predictor. With these two products, we have established ourselves as the experts in protein stability
Lavie Administrative Services is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.